Drisapersen

DRUG4 trials

Sponsors

BioMarin Pharmaceutical, GlaxoSmithKline

Conditions

Duchenne Muscular DystrophyMuscular Dystrophies

Phase 2

A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration

TerminatedNCT01910649

BioMarin PharmaceuticalMuscular Dystrophies

Start: 2008-03-31End: 2016-09-30Updated: 2016-11-07

Phase 3

A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects

TerminatedNCT01803412

BioMarin PharmaceuticalMuscular Dystrophies

Start: 2013-05-01End: 2016-10-01Updated: 2018-06-14

Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol

WithdrawnNCT01890798

GlaxoSmithKlineMuscular Dystrophies

Start: 2014-01-31End: 2015-07-31Updated: 2014-03-24

Unknown Phase

Extension Study of Drisapersen in DMD Subjects

BioMarin PharmaceuticalDuchenne Muscular Dystrophy

Updated: 2018-01-24

Related Papers

Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study

PLoS ONE2016-09-0288 citations